Research programme: neuregulins - Minerva Neurosciences

Drug Profile

Research programme: neuregulins - Minerva Neurosciences

Alternative Names: CNS growth factors - Mind-NRG; MIN-301; NRG-101

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProteoSys
  • Developer Minerva Neurosciences; ProteoSys
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Neuregulins; Recombinant proteins
  • Mechanism of Action ERBB 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 09 Aug 2017 MIN 301 is still in preclinical trials for Parkinson's disease in Switzerland
  • 04 Aug 2017 Minerva Neurosciences plans to file an IND application for MIN 301 in Parkinson's disease
  • 14 Mar 2016 Minerva Neurosciences has patents pending for MIN 301 in US, Japan, Brazil, Canada, Mexico and China (Minerva Neurosciences 10-k, March 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top